Urokinase: Difference between revisions
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
|genericName=Urokinase | |genericName=Urokinase | ||
|aOrAn=a | |aOrAn=a | ||
|drugClass=[[thrombolytic]] | |drugClass=[[thrombolytic agent]] | ||
|indicationType=treatment | |indicationType=treatment | ||
|indication=[[pulmonary embolism]] | |indication=[[pulmonary embolism]] | ||
| Line 14: | Line 14: | ||
:* Loading dose: '''4,400 IU/kg'' at a rate of '''90 mL/h''' over a period of '''10 minutes.''' | :* Loading dose: '''4,400 IU/kg'' at a rate of '''90 mL/h''' over a period of '''10 minutes.''' | ||
:* Maintenance dose: Continuous infusion of '''4,400 IU/kg/h''' at a rate of '''15 mL''' for '''12 hours'''. | :* Maintenance dose: Continuous infusion of '''4,400 IU/kg/h''' at a rate of '''15 mL''' for '''12 hours'''. | ||
| | |contraindications=The use of urokinase is contraindicated in patients with a history of hypersensitivity to the product. | ||
* | Because thrombolytic therapy increases the risk of bleeding, urokinase is contraindicated in the situations listed below. | ||
*Active internal bleeding | |||
*Recent (e.g., within two months) cerebrovascular accident | |||
*Recent (e.g., within two months) intracranial or intraspinal surgery | |||
*Recent trauma including cardiopulmonary resuscitation | |||
*Intracranial neoplasm, arteriovenous malformation, or aneurysm | |||
*Known bleeding diatheses | |||
*Severe uncontrolled arterial hypertension | |||
|warnings======Conidition 1===== | |warnings======Conidition 1===== | ||
Revision as of 13:48, 11 July 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alejandro Lemor, M.D. [2]
Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Overview
Urokinase is a thrombolytic agent that is FDA approved for the treatment of pulmonary embolism. Common adverse reactions include bleeding nd [anaphylaxis]].
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
Pulmonary Embolism
- Dosing Information
- Loading dose: 4,400 IU/kg at a rate of 90 mL/h' over a period of 10 minutes.
- Maintenance dose: Continuous infusion of 4,400 IU/kg/h at a rate of 15 mL for 12 hours.
Off-Label Use and Dosage (Adult)
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
There is limited information regarding Urokinase FDA-Labeled Indications and Dosage (Pediatric) in the drug label.
Off-Label Use and Dosage (Pediatric)
Contraindications
The use of urokinase is contraindicated in patients with a history of hypersensitivity to the product.
Because thrombolytic therapy increases the risk of bleeding, urokinase is contraindicated in the situations listed below.
- Active internal bleeding
- Recent (e.g., within two months) cerebrovascular accident
- Recent (e.g., within two months) intracranial or intraspinal surgery
- Recent trauma including cardiopulmonary resuscitation
- Intracranial neoplasm, arteriovenous malformation, or aneurysm
- Known bleeding diatheses
- Severe uncontrolled arterial hypertension
Warnings
Conidition 1
(Description)
Adverse Reactions
Clinical Trials Experience
Central Nervous System
- (list/description of adverse reactions)
Cardiovascular
- (list/description of adverse reactions)
Respiratory
- (list/description of adverse reactions)
Gastrointestinal
- (list/description of adverse reactions)
Hypersensitive Reactions
- (list/description of adverse reactions)
Miscellaneous
- (list/description of adverse reactions)
Condition 2
Central Nervous System
- (list/description of adverse reactions)
Cardiovascular
- (list/description of adverse reactions)
Respiratory
- (list/description of adverse reactions)
Gastrointestinal
- (list/description of adverse reactions)
Hypersensitive Reactions
- (list/description of adverse reactions)
Miscellaneous
- (list/description of adverse reactions)
Postmarketing Experience
(Description)
Drug Interactions
- Drug 1
- Drug 2
- Drug 3
- Drug 4
- Drug 5
Drug 1
(Description)
Drug 2
(Description)
Drug 3
(Description)
Drug 4
(Description)
Drug 5
(Description)
Use in Specific Populations
Pregnancy
Pregnancy Category (FDA):
(Description)
Pregnancy Category (AUS):
(Description)
Labor and Delivery
(Description)
Nursing Mothers
(Description)
Pediatric Use
(Description)
Geriatic Use
(Description)
Gender
(Description)
Race
(Description)
Renal Impairment
(Description)
Hepatic Impairment
(Description)
Females of Reproductive Potential and Males
(Description)
Immunocompromised Patients
(Description)
Others
(Description)
Administration and Monitoring
Administration
(Oral/Intravenous/etc)
Monitoring
Condition 1
(Description regarding monitoring, from Warnings section)
Condition 2
(Description regarding monitoring, from Warnings section)
Condition 3
(Description regarding monitoring, from Warnings section)
IV Compatibility
Solution
Compatible
- Solution 1
- Solution 2
- Solution 3
Not Tested
- Solution 1
- Solution 2
- Solution 3
Variable
- Solution 1
- Solution 2
- Solution 3
Incompatible
- Solution 1
- Solution 2
- Solution 3
Y-Site
Compatible
- Solution 1
- Solution 2
- Solution 3
Not Tested
- Solution 1
- Solution 2
- Solution 3
Variable
- Solution 1
- Solution 2
- Solution 3
Incompatible
- Solution 1
- Solution 2
- Solution 3
Admixture
Compatible
- Solution 1
- Solution 2
- Solution 3
Not Tested
- Solution 1
- Solution 2
- Solution 3
Variable
- Solution 1
- Solution 2
- Solution 3
Incompatible
- Solution 1
- Solution 2
- Solution 3
Syringe
Compatible
- Solution 1
- Solution 2
- Solution 3
Not Tested
- Solution 1
- Solution 2
- Solution 3
Variable
- Solution 1
- Solution 2
- Solution 3
Incompatible
- Solution 1
- Solution 2
- Solution 3
TPN/TNA
Compatible
- Solution 1
- Solution 2
- Solution 3
Not Tested
- Solution 1
- Solution 2
- Solution 3
Variable
- Solution 1
- Solution 2
- Solution 3
Incompatible
- Solution 1
- Solution 2
- Solution 3
Overdosage
Acute Overdose
Signs and Symptoms
(Description)
Management
(Description)
Chronic Overdose
Signs and Symptoms
(Description)
Management
(Description)
Pharmacology
Urokinase
| |
| Systematic (IUPAC) name | |
| ? | |
| Identifiers | |
| CAS number | ? |
| ATC code | ? |
| PubChem | ? |
| Chemical data | |
| Formula | ? |
| Mol. mass | ? |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Mechanism of Action
(Description)
Structure
(Description with picture)
Pharmacodynamics
(Description)
Pharmacokinetics
(Description)
Nonclinical Toxicology
(Description)
Clinical Studies
Condition 1
(Description)
Condition 2
(Description)
Condition 3
(Description)
How Supplied
(Description)
Storage
There is limited information regarding Urokinase Storage in the drug label.
Images
Drug Images
{{#ask: Page Name::Urokinase |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}
Package and Label Display Panel
{{#ask: Label Page::Urokinase |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}
Patient Counseling Information
(Patient Counseling Information)
Precautions with Alcohol
Alcohol-Urokinase interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
Brand Names
There is limited information regarding Urokinase Brand Names in the drug label.
Look-Alike Drug Names
- (Paired Confused Name 1a) — (Paired Confused Name 1b)
- (Paired Confused Name 2a) — (Paired Confused Name 2b)
- (Paired Confused Name 3a) — (Paired Confused Name 3b)
Drug Shortage Status
Drug Shortage
Price
References
The contents of this FDA label are provided by the National Library of Medicine.